Related Content
Search Google Scholar for:
More Information
Related Jobs from ScienceCareers
|
|
Science 28 June 1996:
Vol. 272. no. 5270, pp. 1886 - 0
DOI: 10.1126/science.272.5270.1886
|
|
Perspective
Douglas D. Richman
Douglas Richman (University of
California at San Diego, USA) captures the current excitement in the
field of HIV therapeutics. New drugs, new treatment regimens, and new
insights into the relation of disease progression to the quantity of
viral RNA in patients' plasma have led to an unprecedented sense of
optimism among researchers.
The author is at the San Diego Veterans Affairs Medical Center,
and in the Departments of Pathology and Medicine, University of
California, Clinical Sciences Building, Room 327, 9500 Gilman Drive, La
Jolla, CA 92092-0679, USA.
Volume 272, Number 5270,
Issue of 28 June 1996,
pp. 1886-1888
©1996 by The American Association for the Advancement of Science.
Read the Full Text
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Comparative Evaluation of the Inhibitory Activities of a Series of Pyrimidinedione Congeners That Inhibit Human Immunodeficiency Virus Types 1 and 2.
- R. W. Buckheit Jr., T. L. Hartman, K. M. Watson, S.-G. Chung, and E.-H. Cho (2008)
Antimicrob. Agents Chemother.
52, 225-236
| Abstract »
| Full Text »
| PDF »
- Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients.
- D. Trabattoni, S. Lo Caputo, M. Biasin, E. Seminari, M. Di Pietro, G. Ravasi, F. Mazzotta, R. Maserati, and M. Clerici (2002)
Clin. Vaccine Immunol.
9, 1114-1118
| Abstract »
| Full Text »
| PDF »
- Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.
- B. N. Phenix, J. J. Lum, Z. Nie, J. Sanchez-Dardon, and A. D. Badley (2001)
Blood
98, 1078-1085
| Abstract »
| Full Text »
| PDF »
- Efficacy of Antiretroviral Agents against Murine Replication-Competent Retrovirus Infection in Human Cells.
- S. K. Powell, M. Artlip, M. Kaloss, S. Brazinski, R. Lyons, G. J. McGarrity, and E. Otto (1999)
J. Virol.
73, 8813-8816
| Abstract »
| Full Text »
| PDF »
- Enhanced Inhibition of Human Immunodeficiency Virus Type 1 by Met-Stromal-Derived Factor 1beta Correlates with Down-Modulation of CXCR4.
- O. O. Yang, S. L. Swanberg, Z. Lu, M. Dziejman, J. McCoy, A. D. Luster, B. D. Walker, and S. H. Herrmann (1999)
J. Virol.
73, 4582-4589
| Abstract »
| Full Text »
- Clinical Progress and the Future of HIV Exceptionalism.
- R. Bayer (1999)
Arch Intern Med
159, 1042-1048
| Abstract »
| Full Text »
| PDF »
- Irreversible Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Dicaffeoylquinic Acids.
- K. Zhu, M. L. Cordeiro, J. Atienza, W. E. Robinson Jr., and S. A. Chow (1999)
J. Virol.
73, 3309-3316
| Abstract »
| Full Text »
- Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays.
- J. M. Raboud, E. Seminari, S. L. Rae, P. R. Harrigan, R. S. Hogg, B. Conway, C. Sherlock, M. T. Schechter, M. V. O'Shaughnessy, and J. S. G. Montaner (1998)
J. Clin. Microbiol.
36, 3369-3371
| Abstract »
| Full Text »
- An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
- P. Andre, M. Groettrup, P. Klenerman, R. de Giuli, B. L. Booth Jr., V. Cerundolo, M. Bonneville, F. Jotereau, R. M. Zinkernagel, and V. Lotteau (1998)
PNAS
95, 13120-13124
| Abstract »
| Full Text »
| PDF »
- Clinical Implications of Resistance to Antiretroviral Drugs.
- (1997)
AIDS Clinical Care
1997, 1
| Full Text »
- Current Problems and the Future of Antiretroviral Drug Trials.
- J. M. Lange (1997)
Science
276, 548-550
| Abstract »
| Full Text »
- XI International AIDS Conference: New Antiretroviral Therapy Guidelines.
- (1996)
AIDS Clinical Care
1996, 2
| Full Text »
|
|
